Application of the Belle.AI Dermatological Image Reference System for Patient Diagnosis in an Active Clinical Setting

Launched by BELLETORUS CORPORATION · Dec 5, 2024

Keywords

ClinConnect Summary

This clinical trial is testing a new tool that uses artificial intelligence (AI) to help doctors and other healthcare providers assess skin conditions. The tool is an app that works on smartphones, showing reference images of various skin issues. It's important to note that the AI does not make any diagnoses; instead, it helps providers by giving them images to compare with what they see in their patients. The study aims to see how well the AI-supported diagnoses from primary care providers match the diagnoses made by expert dermatologists, who are considered the gold standard in skin health.

To participate in this trial, patients need to visit a walk-in clinic with a skin problem and be able to give their consent. They should also have a smartphone with internet access for taking pictures. The trial is open to all adults, but it won’t include young patients with specific privacy concerns. Participants can expect to have their skin condition assessed with the help of this new AI tool, while their healthcare provider uses their training and experience to make the final diagnosis. Overall, this trial could help improve how skin conditions are diagnosed in primary care settings.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Patient must present to walk-in clinic with a primary dermatological complaint.
• • Patient must have the ability and willingness to provide informed consent and comply with study procedures and visits.
• • Participants must have access to the required technology (e.g., smartphone with internet access) and be capable of using it for the required image capture.
• Exclusion Criteria:
• • Patients who are unable to comply with study procedures due to physical or mental health limitations (as assessed by study coordinator).
• • Pediatric, adolescent, and teen patients who present with dermatological conditions on their genitalia will not be included in the study (in support of patient privacy concerns).